Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1J-tube----[1] 6
2J01GB01----[1] 299
3J05A F01----[1] 135
4J05AG04----[1] 18
5J07AH07----[1] 14
6J1081----[1] 56
7J695----[1] 96
8J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0----[1] 96
9JAK 3----[1] 46
10JAK 3 Ritlecitinib----[1] 46
11JAK Inhibitor----[1] 50
12JAK1 / JAK2 Inhibitor----[1] 46
13JAK1 / JAK2 Inhibtor----[1] 46
14Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets[1] Acetylcysteine[1] D00221 --[1] 85
15Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets[1] Acetylcysteine[1] D00221 --[1] 85
16Jaktinib Hydrochloride Tablets----[1] 271
17Janus Kinase Inhibitor----[1] 97
18Jardiance[1] Empagliflozin[1] D10459 [1] SLC5A2 💬-[1] 65
19JBPOS0101[1] JBPOS0101---[1] 145
20JBT-101----[4] 49, 50, 51, 299
21JBT-101 (lenabasum)----[1] 299
22Jejunal extension tube----[1] 6
23Jejunal extension tube (J-tube)----[1] 6
24Jevity 1.0----[1] 2
25Jevity 1.5----[1] 2
26JHL1101----[1] 46
27Jianpixiaozhong particles and Wuse Dietotherapy----[1] 222
28Jin-shui Huan-xian granule----[1] 85
29Jinarc[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
30JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
31JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
32JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
33JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
34JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
35Jinarc - Tolvaptan tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
36Jinarc 15 mg tablets, Jinarc 45 mg tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
37Jinarc 30 mg Tablet[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
38Jinarc 30 mg tablets, 90 mg tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
39Jinarc 30 mg tablets, Jinarc 60 mg tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
40Jinarc® 15mg Tablet[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
41Jinarc® 30 Tablet[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
42Jing Si Herbal Tea LIQUID PACKETS----[2] 46, 271
43Jintropin AQ----[1] 78
44JKB-122----[1] 95
45JKB-122 in capsule or tablet form----[1] 95
46JM----[2] 6, 13
47JM-010----[1] 6
48JM-010 group A----[1] 6
49JM-010 group B----[1] 6
50JM-4----[1] 13
51JNJ 38518168----[1] 46
52JnJ 54767414----[1] 28
53JNJ-16240159-AAC----[1] 46
54JNJ-31001074----[1] 6
55JNJ-38518168----[1] 46
56JNJ-38518168 (10 mg)----[1] 46
57JNJ-38518168 (3 mg)----[1] 46
58JNJ-38518168 (30 mg)----[1] 46
59JNJ-38518168 / MTX----[1] 46
60JNJ-38518168 50-mg Over Encapsulated Tablet----[1] 46
61JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg----[1] 46
62JNJ-38518168-ZBQ----[1] 46
63JNJ-38518168-ZBQ - film-coated tablet - 10 mg----[1] 46
64JNJ-38518168-ZBQ - film-coated tablet - 10mg----[1] 46
65JNJ-38518168-ZBQ - film-coated tablet - 3 mg----[1] 46
66JNJ-38518168-ZBQ - film-coated tablet - 30 mg----[1] 46
67JNJ-38518168-ZBQ - film-coated tablet - 30mg----[1] 46
68JNJ-38518168-ZBQ - film-coated tablet - 3mg----[1] 46
69JNJ-39039039----[1] 210
70JNJ-39758979----[1] 46
71JNJ-39758979 (10 mg)----[1] 46
72JNJ-39758979 (100 mg)----[1] 46
73JNJ-39758979 (30 mg)----[1] 46
74JNJ-39758979 (300 mg)----[1] 46
75JNJ-39758979 / MTX----[1] 46
76JNJ-39758979-AAC - enteric coated tablet - 10 mg----[1] 46
77JNJ-39758979-AAC - enteric coated tablet - 100 mg----[1] 46
78JNJ-39758979-AAC - enteric coated tablet - 30 mg----[1] 46
79JNJ-40346527[1] JNJ-40346527---[2] 46, 96
80JNJ-40346527-AAC[1] JNJ-40346527---[1] 96
81JNJ-40346527-AAC - capsule - 50 mg[1] JNJ-40346527---[1] 46
82JNJ-42160443----[1] 226
83JNJ-54767414----[2] 28, 49
84JNJ-54781532 150 mg once daily----[1] 97
85JNJ-54781532 25 mg once daily----[1] 97
86JNJ-54781532 75 mg once daily----[1] 97
87JNJ-54781532 75 mg twice daily----[1] 97
88JNJ-54781532-AAD-10 mg----[1] 97
89JNJ-54781532-AAD-30 mg----[1] 97
90JNJ-54781532-AAD-5 mg----[1] 97
91JNJ-55920839----[1] 49
92JNJ-56022473----[1] 49
93JNJ-64304500----[1] 96
94JNJ-64304500-AAA----[1] 96
95JNJ-66525433----[1] 97
96JNJ-67484703----[1] 46
97JNJ-67864238----[1] 96
98JNJ-67896049----[1] 86
99JNJ-67896049 (ACT-293987)----[1] 86
100JNJ-67896062 / ACT-064992----[2] 86, 88
101JNJ-67896062/ ACT-064992----[2] 86, 88
102JNJ-72537634----[1] 97
103JNJ-78934804----[2] 96, 97
104JNJ-80202135----[4] 11, 46, 49, 53
105JNJ31-31001074----[1] 6
106Jojoba oil[1] Jojoba oil---[1] 36
107Jojoba oil with broccoli sprout extract[2] Broccoli,
Jojoba oil		---[1] 36
108Jorveza[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
109Jorveza 0.5 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
110Jorveza 0.5 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
111Jorveza 1 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
112Jorveza 1 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
113JP 1730----[1] 6
114JP-1730/F01----[2] 6, 17
115JP-1730/F02----[2] 6, 17
116JP-1730/F03----[2] 6, 17
117JR-141----[1] 19
118JR-141 or Idursulfase[1] Idursulfase[1] D04499 [1] IDS 💬[3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬[1] 19
119JR-171----[1] 19
120JS002----[1] 79
121JS005----[1] 271
122JSP191----[1] 285
123JTE-051----[1] 46
124JTT-251----[1] 86
125Juanbi pill----[1] 46
126Juvit D3----[1] 6
127Jyseleca[1] Filgotinib[1] D10871 [1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46
128Jyseleca 100 mg film-coated tablets[1] Filgotinib[1] D10871 [1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46
129Jyseleca 200 mg film-coated tablets[1] Filgotinib[1] D10871 [1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46
130JZP-110----[1] 6